Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 31.32x | 3/4 | $22.72B | $272.28 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.22x | 4/4 | $10.76B | $128.93 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 42.53x | 4/4 | $29.03B | $347.86 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 31.32x | 3/4 | $22.72B | $272.28 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.22x | 4/4 | $10.76B | $128.93 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 42.53x | 4/4 | $29.03B | $347.86 | Included in the active peer mix. |